Febantel + Praziquantel + Pyrantel

Verify with FDA CVM →

625 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
625
Total Reports
27
Deaths Reported
430.0%
Death Rate

Active Ingredients

FebantelPraziquantelPyrantel

Administration Routes

OralUnknownTopicalParenteral

Species Affected

Dog 607
Unknown 9
Cat 7
Human 2

Most Affected Breeds

Dog (unknown) 131
Greyhound 76
Crossbred Canine/dog 45
Retriever - Labrador 36
Retriever - Golden 28
Shepherd Dog - German 20
Beagle 14
Chihuahua 13
Pit Bull 13
Unknown 12

Most Reported Reactions

Vomiting 152
Lack of efficacy (endoparasite) - tapeworm 82
Lack of efficacy (endoparasite) - hookworm 73
Diarrhoea 64
INEFFECTIVE, HOOKS 53
Emesis 46
Emesis (multiple) 42
Lack of efficacy (endoparasite) - NOS 32
Lack of efficacy (endoparasite) - roundworm NOS 29
Hyperactivity 28
Lethargy (see also Central nervous system depression in 'Neurological') 27
Other abnormal test result NOS 20

Outcome Breakdown

Outcome Unknown
312 (50.6%)
Recovered/Normal
246 (39.9%)
Ongoing
31 (5.0%)
Died
19 (3.1%)
Euthanized
8 (1.3%)

Data Summary

Metric Value
Total adverse event reports 625
Reports involving death 27
Case-fatality rate (reported events) 430.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Febantel + Praziquantel + Pyrantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 625 adverse event reports referencing Febantel + Praziquantel + Pyrantel, including 27 reports in which the animal died — a 430.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Febantel, Praziquantel, Pyrantel. Reported administration routes include Oral, Unknown, Topical, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Febantel + Praziquantel + Pyrantel reports are Dog (607 reports), Unknown (9 reports), Cat (7 reports), with Dog accounting for the largest share. Within those species, Dog (unknown) (131), Greyhound (76), Crossbred Canine/dog (45) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Febantel + Praziquantel + Pyrantel are Vomiting (152), Lack of efficacy (endoparasite) - tapeworm (82), Lack of efficacy (endoparasite) - hookworm (73), Diarrhoea (64). Of the 616 reports with a coded outcome, Outcome Unknown is the leading category at 50.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Febantel + Praziquantel + Pyrantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial